Davis Polk advised Auris Medical Holding AG on its $10 million public offering of 10,000,000 of its common shares and 10,000,000 warrants, each warrant entitling its holder to purchase 0.7 of a common share. The common shares are listed on the NASDAQ Global Market under the symbol “EARS.” 

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere’s disease and vestibular vertigo (AM-125) and early-stage research and development projects. The company was founded in 2003 and is headquartered in Zug, Switzerland.

The Davis Polk capital markets team included partner Sophia Hudson and associate Pedro J. Bermeo. The tax team included partner Kathleen L. Ferrell and associate Andrew Imber. Associate Colleen Blanco provided 1940 Act advice. All members of the Davis Polk team are based in the New York office. 

Copy link to share post